Adrenal Glands

adrenal-glandsAnatomy of the adrenal glands:

Adrenal glands, which are also called suprarenal glands, are small, triangular glands located on top of both kidneys. An adrenal gland is made of two parts: the outer region is called the adrenal cortex and the inner region is called the adrenal medulla.

Function of the adrenal glands:

The adrenal glands work interactively with the hypothalamus and pituitary gland in the following process:

  • the hypothalamus produces corticotropin-releasing hormones, which stimulate the pituitary gland.
  • the pituitary gland, in turn, produces corticotropin hormones, which stimulate the adrenal glands to produce corticosteroid hormones.

Both parts of the adrenal glands — the adrenal cortex and the adrenal medulla — perform very separate functions.

What is the adrenal cortex?

The adrenal cortex, the outer portion of the adrenal gland, secretes hormones that have an effect on the body’s metabolism, on chemicals in the blood, and on certain body characteristics. The adrenal cortex secretes corticosteroids and other hormones directly into the bloodstream. The hormones produced by the adrenal cortex include:

  • corticosteroid hormones
    • hydrocortisone hormone – this hormone, also known as cortisol, controls the body’s use of fats, proteins, and carbohydrates.
    • corticosterone – this hormone, together with hydrocortisone hormones, suppresses inflammatory reactions in the body and also affects the immune system.
  • aldosterone hormone – this hormone inhibits the level of sodium excreted into the urine, maintaining blood volume and blood pressure.
  • androgenic steroids (androgen hormones) – these hormones have minimal effect on the development of male characteristics.

What is the adrenal medulla?

The adrenal medulla, the inner part of the adrenal gland, is not essential to life, but helps a person in coping with physical and emotional stress. The adrenal medulla secretes the following hormones:

  • epinephrine (also called adrenaline) – this hormone increases the heart rate and force of heart contractions, facilitates blood flow to the muscles and brain, causes relaxation of smooth muscles, helps with conversion of glycogen to glucose in the liver, and other activities.
  • norepinephrine (also called noradrenaline) – this hormone has little effect on smooth muscle, metabolic processes, and cardiac output, but has strong vasoconstrictive effects, thus increasing blood pressure.

From: University of Maryland Center for Diabetes and Endocrinology

Pasireotide for the treatment of Cushing’s disease

Posted online on June 17, 2013. (doi:10.1517/21678707.2013.807731)

Annamaria Colao Chiara Simeoli Monica De Leo Alessia Cozzolino Rosario Pivonello

Department of Clinical Medicine and Surgery, Section of Endocrinology, Federico II University, Via Sergio Pansini 5,

80131 Naples

, Italy +39 0817462132; +39 0815465443; colao@unina.it

Author for correspondence

Introduction: Pasireotide, a novel multireceptor targeted somatostatin analog is the first drug approved for treatment of adult patients with Cushing’s disease (CD) for whom pituitary surgery is not an option or has not been curative.

Areas covered: The review describes published data on efficacy and safety of pasireotide in CD patients. In particular, the review focuses on a Phase III study (CSOM230B2305) evaluating the outcomes of treatment with pasireotide at the doses of 600 and 900 µg twice daily for 12 months in 162 CD patients. This clinical trial reported a decrease in urinary free cortisol levels in the majority of patients, with a substantial reduction in nearly half and a normalization in > 25% of patients included in the study, accompanied by an improvement in clinical picture as well as a significant reduction in pituitary tumor size. Hyperglycemia appears as the most important side effect, requiring a careful monitoring and a prompt administration of glucose-lowering medications.

Expert opinion: Pasireotide seems to have a promising role as medical option for CD patients who experienced a failure or not candidate for neurosurgery; its employment will probably induce in the near future significant changes in the therapeutic approach to CD.

Read More: http://informahealthcare.com/doi/abs/10.1517/21678707.2013.807731

Information for Cushing’s Patients on Korlym

Please note – On July 1st, Korlym will not be supplied by Curascript and Accredo any more.

Korlym will continue to be available, just through a different pharmacy called Centric Health Resources.  They are trying to reach all of you to introduce you to their program and enhanced services as well as set up your next shipment.

If you have not yet spoken with them, please call them at 866-758-7138.

For reference, their website is: http://www.centrichealthresources.com/

Upcoming Endocrinology Conferences

73rd Scientific Sessions (2013) of American Diabetes Association CME 
June 21-25, 2013 -Chicago, Illinois, United States

6th International Conference on Childrens Bone Health CME 
June 22-25, 2013 -Rotterdam, Netherlands

2013 Annual Meeting of the Society for Behavioral Neuroendocrinology CME 
June 23-26, 2013 -Atlanta, Georgia, United States

17th Annual Conference on Hypertension – Focus on Hypertension, Diabetes and Dyslipidemia CME 
June 28-30, 2013 -Charleston, South Carolina, United States

Bone Densitometry Comprehensive Exam Review CME 
August 3, 2013 -Houston, Texas, United States

4th World Congress on Diabetes & Metabolism CME 
August 14-16, 2013 -Skokie, Illinois, United States

Anti-Aging Medicine: Advances in Hormone Replacement CME 
August 17-18, 2013 -Chicago, Illinois, United States

World Congress on Endocrinology 2013 CME 
August 26-28, 2013 -Raleigh, North Carolina, United States

HBPR 2013: High Blood Pressure Research 2013 Scientific Sessions CME 
September 11-14, 2013 -New Orleans, Louisiana, United States

35th Annual British Andrology Society Meeting CME 
September 13-14, 2013 -Liverpool, United Kingdom

5th Florence-Utah Symposium on Genetics of Male Infertility 
September 19-21, 2013 -Florence, Italy

2013 Cardiometabolic Health Congress CME 
October 2-5, 2013 -Boston, Massachusetts, United States

Bone Densitometry: Principles and Procedures CME 
October 5-6, 2013 -Houston, Texas, United States

11th Annual Meeting of Androgen Excess & PCOS Society CME 
October 17-18, 2013 -Newport, Rhode Island, United States

AAES 2014 Annual Meeting CME 
April 27-29, 2014 -Boston, Massachusetts, United States

74th Scientific Sessions of American Diabetes Association CME 
June 13-17, 2014 -San Francisco, California, United States

50th EASD Annual Meeting CME 
September 15-19, 2014 -Vienna, Austria

84th Annual Meeting of the American Thyroid Association CME 
October 29 – November 2, 2014 -Coronado, California, United States

ENDO 2015 CME 
March 5-8, 2015 -San Diego, California, United States

AAES 2015 Annual Meeting CME 
May 17-19, 2015 -Nashville, Tennessee, United States

Research and Markets: Pituitary ACTH Hypersecretion (Cushing’s Disease) – Pipeline Review Report, H1 2013 Edition

Research and Markets(http://www.researchandmarkets.com/research/rdf6gm/pituitary_acth) has announced the addition of the “Pituitary ACTH Hypersecretion (Cushing’s Disease) – Pipeline Review, H1 2013” report to their offering.

‘Pituitary ACTH Hypersecretion (Cushing’s Disease) – Pipeline Review, H2 2013’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing’s Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing’s Disease).

Scope

– A snapshot of the global therapeutic scenario for Pituitary ACTH Hypersecretion (Cushing’s Disease).

– A review of the Pituitary ACTH Hypersecretion (Cushing’s Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

– Coverage of products based on various stages of development ranging from discovery till registration stages.

– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

– Coverage of the Pituitary ACTH Hypersecretion (Cushing’s Disease) pipeline on the basis of route of administration and molecule type.

– Key discontinued pipeline projects.

– Latest news and deals relating to the products.

Companies Involved in Pituitary ACTH Hypersecretion (Cushing’s Disease) Therapeutics Development

 

  • Isis Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Novartis AG
  • HRA Pharma, SA
  • Cortendo Invest AB

 

Drug Profiles: Product Description, Mechanism of Action and R&D Progress

 

  • LCI-699
  • mifepristone
  • ISIS-GCCRRx
  • Inhibitors of ACTH receptor
  • ketoconazole
  • Next Generation Cortisol Inhibitor
  • pasireotide Long Acting Release

 

For more information visit http://www.researchandmarkets.com/research/rdf6gm/pituitary_acth